A randomized, rater-blinded cross-over multicenter study comparing the clinical efficacy of Ritalin® LA (methylphenidate) treatment (20 or 40 mg orally o.d.) in children with ADHD under different b...
This historical record does not confirm current site availability.
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with ADHD. Other eligibility criteria applied.
- Listed locations
- Germany
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Novartis Pharma GmbH
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Germany
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-006441-14
- Official title
Show the full official title
A randomized, rater-blinded cross-over multicenter study comparing the clinical efficacy of Ritalin® LA (methylphenidate) treatment (20 or 40 mg orally o.d.) in children with ADHD under different b...
Recruitment & locations
CompletedGermany
Registry details
- Germany — Completed
Questions about this study
Who is behind this study?
The study sponsor is Novartis Pharma GmbH, a pharmaceutical company.
Who was this study for?
This study was for people with ADHD. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me